the high cost of weight loss drugs
Between 2019 and 2023, the number of outpatient Medicaid prescriptions for select GLP-1s to treat diabetes and obesity grew from 755,300 to 3.8 million. During the same period, Medicaid spending on those drugs increased from $597.3 million to $3.9 billion.


